AR057227A1 - Metodo para usar antagonistas de il6 con inhibidores del proteasoma - Google Patents

Metodo para usar antagonistas de il6 con inhibidores del proteasoma

Info

Publication number
AR057227A1
AR057227A1 ARP060105416A ARP060105416A AR057227A1 AR 057227 A1 AR057227 A1 AR 057227A1 AR P060105416 A ARP060105416 A AR P060105416A AR P060105416 A ARP060105416 A AR P060105416A AR 057227 A1 AR057227 A1 AR 057227A1
Authority
AR
Argentina
Prior art keywords
proteasome inhibitor
leucyl
antagonist
treatment
condition
Prior art date
Application number
ARP060105416A
Other languages
English (en)
Spanish (es)
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of AR057227A1 publication Critical patent/AR057227A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP060105416A 2005-12-09 2006-12-07 Metodo para usar antagonistas de il6 con inhibidores del proteasoma AR057227A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74915205P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
AR057227A1 true AR057227A1 (es) 2007-11-21

Family

ID=38123650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105416A AR057227A1 (es) 2005-12-09 2006-12-07 Metodo para usar antagonistas de il6 con inhibidores del proteasoma

Country Status (15)

Country Link
US (1) US20090022726A1 (https=)
EP (1) EP1954310A4 (https=)
JP (1) JP2009518447A (https=)
KR (1) KR20080072761A (https=)
CN (1) CN101325969A (https=)
AR (1) AR057227A1 (https=)
AU (1) AU2006321610A1 (https=)
BR (1) BRPI0619498A2 (https=)
CA (1) CA2632732A1 (https=)
EA (1) EA014675B1 (https=)
IL (1) IL191694A0 (https=)
NO (1) NO20082907L (https=)
TW (1) TW200803895A (https=)
WO (1) WO2007067976A2 (https=)
ZA (1) ZA200805956B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2030981B1 (en) 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
AR058135A1 (es) * 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2007208678B2 (en) * 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
CA2728243C (en) * 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
EA201170527A1 (ru) * 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
KR20160091440A (ko) * 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011006273A1 (en) 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
WO2011013786A1 (ja) * 2009-07-31 2011-02-03 Maeda Shin 癌の転移抑制剤
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
US20140294854A1 (en) * 2011-03-10 2014-10-02 Albert Einstein College Of Medicine Of Yeshiva University Target directed to adipocytes, methods and assays for treatment of obesity
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2017138008A2 (en) * 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
KR20010080267A (ko) * 1998-10-20 2001-08-22 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아솜 억제제 약물 작용을 모니터링하는 방법
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
WO2004071404A2 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of il-6 antagonists in combination with steroids to enhance apoptosis
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها

Also Published As

Publication number Publication date
EP1954310A2 (en) 2008-08-13
CA2632732A1 (en) 2007-06-14
TW200803895A (en) 2008-01-16
US20090022726A1 (en) 2009-01-22
EA200870029A1 (ru) 2008-10-30
KR20080072761A (ko) 2008-08-06
ZA200805956B (en) 2009-10-28
IL191694A0 (en) 2008-12-29
AU2006321610A1 (en) 2007-06-14
EP1954310A4 (en) 2009-04-22
JP2009518447A (ja) 2009-05-07
WO2007067976A3 (en) 2008-02-14
EA014675B1 (ru) 2010-12-30
CN101325969A (zh) 2008-12-17
NO20082907L (no) 2008-08-26
WO2007067976A2 (en) 2007-06-14
BRPI0619498A2 (pt) 2011-10-04

Similar Documents

Publication Publication Date Title
AR057227A1 (es) Metodo para usar antagonistas de il6 con inhibidores del proteasoma
ECSP078003A (es) Inhibidores de aspartil proteasas
PE20221628A1 (es) Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
ECSP088959A (es) Inhibidores heterocíclicos de aspartil-proteasa
BRPI0418639B8 (pt) compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
CO6160339A2 (es) Antagonistas de ccr2 para el tratamiento de fibrosis
EP2425858A3 (en) Compositions for treating pain and pruritus
BRPI0605921A2 (pt) compostos orgánicos
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
EA200701756A1 (ru) Соль производного пролина, её сольват и способ её получения
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
JP2004521117A5 (https=)
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
CO5150232A1 (es) METODO Y COMBINACION QUE UTILIZAN (+) NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2]
TW200633703A (en) Salts of n-[2-({3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide
EA200800791A1 (ru) Сульфонилпирролгидрохлориды, как ингибиторы гистондезацетилазы
EA200600267A1 (ru) Антагонисты мускариновых рецепторов ацетилхолина
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
PE20070352A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
CL2010001618A1 (es) Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades.
EA200600787A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal